Astellas To Market Pain Patch Of NeurogesX Of U.S.
This article was originally published in PharmAsia News
Astellas Pharma has agreed to market U.S.-based NeurogesX's patch for relieving pain in Europe, Africa and the Middle East. The drug is Qutenza (capsaicin), which has European Union approval, but is not yet approved in the United States. Under the agreement, Astellas is to pay NeurogesX $42 million upfront for marketing rights. The drug patch is expected to be launched in the first half of next year. (Click here for more
You may also be interested in...
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.